https://www.selleckchem.com/products/atn-161.html
Currently there is a gap between the rate of new antifungal development and the emergence of resistance among Candida clinical strains, particularly threatened by the extreme adhesiveness of C. albicans to indwelling medical devices. Two silver camphorimine complexes, [Ag(OH)OC10H14N(C6H4)2NC10H14O] (compound P) and [Ag(OC10H14NC6H4CH3-p)2(μ-O)] (compound Q), are herein demonstrated as having high inhibiting activity towards the growth of Candida albicans and Candida glabrata clinical strains resistant to azoles, the frontline antifunga
Like
Comment
Share
